David E. Lazar - 18 Dec 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: KALA
Reported as of: 18 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Dec 2025, 17:18:14 UTC
Prior SEC filing: 26 Nov 2025
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for KALA BIO, Inc. (KALA) on 22 Dec 2025.

Key facts

This page summarizes David E. Lazar's Form 4 filing for KALA BIO, Inc. (KALA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Dec 2025, 17:18.

Change

Previous filing in this sequence was filed on 26 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Chief Executive Officer, Director
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 22 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 18 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Convertible Loan

Other

Transaction value
Shares: -368,614
Change %: -100%
Price
Shares after: 0
Date: 18 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 368,614
Exercise price: $1.02
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

No shares of common stock are beneficially owned.

Footnote F2

Not applicable.

Footnote F3

On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash.